Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 15 X users

patent: 4 patents

Citations

dimensions_citation: 121 Dimensions

Readers on

mendeley: 117 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

GENETICALLY MODIFIED NK CELLS AND USES THEREOF

Application EP-4010464-A4

European Patent Office

ENGINEERED EFFECTOR CELLS FOR TRAFFICKING OF ALLOGENEIC CELL THERAPIES IN SOLID TUMORS

Application WO-2023081896-A1

World Intellectual Property Organisation (WIPO)

MODIFIED KILLER CELLS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF

Application WO-2022169291-A1

World Intellectual Property Organisation (WIPO)

COMBINED INVASION AND CYTOTOXICITY ASSAY USING CHEMOKINE SECRETING TARGET CELLS

Application WO-2020028654-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.